Condition
PARP Inhibitor clinical trials and research
As of November 12, 2026, Find a Trial lists 4 PARP Inhibitor clinical trials that are recruiting, at sites in 2 countries (most in China (2), United States (2)). By phase: Phase 1/2 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest PARP Inhibitor clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| SPR1020, a new selective PARP1 drug for adults with advanced solid tumors. | Phase 1/2 | Hefei, Anhui and 12 other locations | Recruiting | Jan 22, 2026 |
| Reducing fatigue in adults with ovarian cancer on PARP inhibitors | — | Aurora, Colorado and 5 other locations | Recruiting | Nov 29, 2024 |
| Assessing safety of combining radiotherapy with new systemic therapies for breast cancer | — | Beijing, Beijing Municipality | Recruiting | Jan 9, 2024 |
| Combining vismodegib and atezolizumab for treating resistant ovarian cancer | Phase 2 | Pittsburgh, Pennsylvania | Recruiting | Sep 13, 2022 |
All recruiting trials (4)
-
SPR1020, a new selective PARP1 drug for adults with advanced solid tumors.
This study will test SPR1020, a highly selective PARP1 inhibitor, in adults with advanced solid tumors—especially cancers with BRCA or other homologous recombination deficiency (HRD) mutations—to find safe doses and look for early signs of benefit.
-
Reducing fatigue in adults with ovarian cancer on PARP inhibitors
This study is testing a tele-health program called REVITALIZE to see if it can help reduce fatigue and improve daily life for adults with ovarian cancer who are taking PARP inhibitors.
-
Assessing safety of combining radiotherapy with new systemic therapies for breast cancer
This study is testing if it's safe to give new breast cancer treatments together with radiation therapy to see if they can work well together for patients who need both.
-
Combining vismodegib and atezolizumab for treating resistant ovarian cancer
This study is testing a new combination of two drugs, vismodegib and atezolizumab, to see if they can help people with ovarian cancer that hasn't responded to standard treatments.
Related topics
Quick answers
How many PARP Inhibitor clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (2 trials), United States (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.